Sana Biotechnology Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
194
- Stock Symbol
-
SANA
- Investments
-
5
- Share Price
-
$1.77
- (As of Friday Closing)
Sana Biotechnology General Information
Description
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Contact Information
Website
www.sana.comCorporate Office
- 188 East Blaine Street
- Suite 400
- Seattle, WA 98102
- United States
Corporate Office
- 188 East Blaine Street
- Suite 400
- Seattle, WA 98102
- United States
Sana Biotechnology Stock Performance
As of 25-Apr-2025, Sana Biotechnology’s stock price is $1.77. Its current market cap is $399M with 225M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.77 | $1.77 | $1.26 - $10.50 | $399M | 225M | 3.55M | -$1.16 |
Sana Biotechnology Financials Summary
As of 31-Dec-2024, Sana Biotechnology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 261,005 | 261,005 | 632,597 | 379,399 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (261,730) | (261,730) | (275,593) | (257,638) |
| Net Income | (266,759) | (266,759) | (283,255) | (269,476) |
| Total Assets | 501,020 | 501,020 | 565,299 | 822,720 |
| Total Debt | 94,197 | 94,197 | 104,096 | 108,253 |
Sana Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sana Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sana Biotechnology Comparisons
Industry
Financing
Details
Sana Biotechnology Competitors (13)
One of Sana Biotechnology’s 13 competitors is Caribou Biosciences, a Formerly VC-backed company based in Berkeley, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Sana Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sana Biotechnology Patents
Sana Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023243626-A1 | Cd4-specific antibody constructs and compositions and uses thereof | Pending | 31-Mar-2022 | ||
| EP-4499706-A2 | Cd4-specific antibody constructs and compositions and uses thereof | Pending | 31-Mar-2022 | ||
| US-20250101382-A1 | Genetically modified cells and compositions and uses thereof | Pending | 11-Mar-2022 | ||
| EP-4479416-A1 | Engineered cd47 proteins and uses thereof | Pending | 17-Feb-2022 | ||
| AU-2023220128-A1 | Engineered cd47 proteins and uses thereof | Pending | 17-Feb-2022 | C07K14/70503 |
Sana Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sana Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sana Biotechnology Investments & Acquisitions (5)
Sana Biotechnology’s most recent deal was a Later Stage VC with Repairon. The deal was made on 01-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Repairon | 01-Jan-2021 | Later Stage VC | Biotechnology | ||
| Oscine Therapeutics | 30-Oct-2020 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Cytocardia | 12-Nov-2019 | Merger/Acquisition | Biotechnology | ||
| Oscine Therapeutics | 11-Jun-2019 | Early Stage VC | Discovery Tools (Healthcare) | ||
| Cobalt Biomedicine | 01-Feb-2019 | Merger/Acquisition | Drug Delivery |
Sana Biotechnology ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
35.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Sana Biotechnology FAQs
-
When was Sana Biotechnology founded?
Sana Biotechnology was founded in 2018.
-
Where is Sana Biotechnology headquartered?
Sana Biotechnology is headquartered in Seattle, WA.
-
What is the size of Sana Biotechnology?
Sana Biotechnology has 194 total employees.
-
What industry is Sana Biotechnology in?
Sana Biotechnology’s primary industry is Biotechnology.
-
Is Sana Biotechnology a private or public company?
Sana Biotechnology is a Public company.
-
What is Sana Biotechnology’s stock symbol?
The ticker symbol for Sana Biotechnology is SANA.
-
What is the current stock price of Sana Biotechnology?
As of 25-Apr-2025 the stock price of Sana Biotechnology is $1.77.
-
What is the current market cap of Sana Biotechnology?
The current market capitalization of Sana Biotechnology is $399M.
-
Who are Sana Biotechnology’s competitors?
Caribou Biosciences, Bristol-Myers Squibb, Amgen, Gilead Sciences, and Merck & Co. are some of the 13 competitors of Sana Biotechnology.
-
What is Sana Biotechnology’s annual earnings per share (EPS)?
Sana Biotechnology’s EPS for 12 months was -$1.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
